It is a modular urinalysis workflow launched by DIRUI, which can meet the realistic needs of clinical laboratories for automated and high-throughput urine testing.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Wondfo (300482.SZ) released its third quarter report for 2022. The company's revenue in the first three quarters was CNY 4.696 billion, up 87.32% year-on-year; net profit attributable to the mother company was CNY 1.240 billion

PerkinElmer reported Tuesday its fiscal third quarter revenues dropped 17 percent year over year on declines in its COVID-19 business and pandemic-related lockdowns in China that dragged down the firm's diagnostics revenue.

Orders for Pacific Biosciences' new Revio long-read sequencing instrument are already rolling in, just a few weeks after its reveal, the company said this week as it announced a year-over-year decrease in third quarter revenues.

In the first three quarters of 2022, the company achieved revenue of CNY 1.18 billion, an increase of 39.32% year-on-year; net profit of CNY 308 million, an increase of 22.42% year-on-year; net profit of CNY 306 million, an increase of 28.84% year-on-year.

Qiagen reported double-digit year-over-year sales growth in its core non-COVID-related product portfolio on Monday afternoon, prompting the company to raise its full-year guidance.

Cepheid said Monday it secured CE-IVD marking for its group B Streptococcus assay, Xpert Xpress GBS, and will start selling the test in Europe this month.

As a leading enterprise in China's in vitro diagnostic industry, Autobio Diagnostics CO.,Ltd. has continued to maintain a steady growth trend.

Illumina, Inc. (Nasdaq: ILMN) today announced its financial results for the third quarter of fiscal year 2022, which include consolidated financial results for GRAIL.

For its first full quarter following a business combination, QuidelOrtho after the close of the market on Wednesday reported third-quarter revenues of $783.8 million, an increase of 54% compared to $509.8 million in Q3 2021 and in line with preliminary estimates announced in October.

Snibe announced its 2022 Q3 report, the company achieved operating revenue of RMB 880 million, up 31.67% year-on-year; net profit attributable to shareholders of the listed company was RMB 355 million, up 49.72% year-on-year.